Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Thoracic 1Plasma cell 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Lung Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

fludarabine phosphate 55Cyclophosphamide 49Peripheral Blood Stem Cell Transplantation 47Mycophenolic Acid 40Tacrolimus 38Whole-Body Irradiation 32Busulfan 27Cyclosporine 25Antilymphocyte Serum 25Methotrexate 21Filgrastim 21fludarabine 19Melphalan 19Radiotherapy 14Methylprednisolone 13Sirolimus 11Flow Cytometry 10Etoposide 10Alemtuzumab 10Cord Blood Stem Cell Transplantation 9Rituximab 8Psychiatric Rehabilitation 8Granulocyte Colony-Stimulating Factor 8Therapeutics 7Polymerase Chain Reaction 7thymoglobulin 6sargramostim 5Prednisone 5Ondansetron 4Immunologic Techniques 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × pemigatinib × Plasma cell × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡